Please login to the form below

Not currently logged in
Email:
Password:

Sutent

This page shows the latest Sutent news and features for those working in and with pharma, biotech and healthcare.

BMS eyes approval for second Opdivo combo in kidney cancer

BMS eyes approval for second Opdivo combo in kidney cancer

plus tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) compared to Pfizer’s older drug Sutent (sunitinib). ... Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the

Latest news

  • NICE turns down Keytruda/Inlyta combo for kidney cancer NICE turns down Keytruda/Inlyta combo for kidney cancer

    In preliminary draft guidance issued this morning, the UK’s medicines cost-effectiveness agency accepts that clinical trials show the combination is better than Pfizer’s older drug Sutent (sunitinib) in ... The EU approval was based on the phase 3

  • FDA clears Blueprint’s $32k-per-month GI cancer drug FDA clears Blueprint’s $32k-per-month GI cancer drug

    imatinib) and Pfizer’s Sutent (sunitinib), which are also available as generics, and Bayer’s Stivarga (regorafenib) which is still in patent.

  • Merck claims key FDA okay for Bavencio in kidney cancer Merck claims key FDA okay for Bavencio in kidney cancer

    free survival (PFS) by 5.4 months for patients with advanced RCC compared with Pfizer’s older drug Sutent (sunitinib). ... Merck/MSD also has overall survival data in hand with its drug, showing a 47% reduction for the combination compared to Sutent.

  • EU approval for Opdivo combo in renal cell cancer EU approval for Opdivo combo in renal cell cancer

    a 37% decreased risk of death in intermediate- and poor-risk patients compared to a Sutent, observed regardless of PD-L1 expression level. ... category with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq plus Avastin to Sutent, which

  • Roche pulls EU Tecentriq/Avastin filing in kidney cancer Roche pulls EU Tecentriq/Avastin filing in kidney cancer

    the duo reduced progression-free survival (PFS) by 26% compared to Pfizer’s Sutent (sunitinib), a standard first-line therapy. ... After a re-examination of the CheckMate-214 trial comparing the combination to Sutent, which was the basis of the

More from news
Approximately 3 fully matching, plus 77 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... This meant that due to lack of data, there was no benefit found for

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics